Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia

Niloufer Khan, Andrew Hantel, Randall W. Knoebel, Andrew Artz, Richard A. Larson, Lucy A. Godley, Michael J. Thirman, Hongtao Liu, Jane E. Churpek, Darren King, Olatoyosi Odenike, Wendy Stock*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Improving therapy for relapsed/refractory AML remains a challenge. We performed a retrospective analysis of outcomes following decitabine treatment in 34 patients with relapsed/refractory AML (median age, 62; median Charlson comorbidity score, 6). Decitabine, 20 mg/m2 daily, was given in 5- (25%) or 10-day (75%) cycles. Overall response rate (OR) was 30% with 21% complete remission and 9% partial remission rate. Patients with therapy-related myeloid neoplasm (t-MN) and secondary AML had a significantly higher OR compared to those with de novo AML (70 vs. 30%; p =.02). Median overall survival of all patients was 8.5 months. Median survival in patients with t-MN or secondary AML was 12.4 months compared to 8 months in those with de novo AML (p =.20). Fifteen (44%) patients proceeded to hematopoietic stem cell transplant. These data support using 10-day treatment cycles of decitabine in patients with relapsed/refractory AML, particularly for those with secondary or therapy-related AML.

Original languageEnglish (US)
Pages (from-to)2127-2133
Number of pages7
JournalLeukemia and Lymphoma
Volume58
Issue number9
DOIs
StatePublished - Sep 2 2017

Keywords

  • acute myeloid leukemia
  • AML
  • Decitabine
  • refractory AML
  • relapsed AML

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this